Hellinger, W C, Smith, T F, Van Scoy, R E et al. · JAMA · 1988
Researchers tested whether a specific blood marker for Epstein-Barr virus (EBV) could help diagnose chronic fatigue. They compared 30 people with chronic fatigue who had very high levels of this EBV marker to 30 healthy people without the marker. They found no meaningful differences between the two groups in their symptoms, physical exams, or other lab results, and this held true at follow-up visits. The study concluded that this particular EBV blood test is not useful for diagnosing or evaluating chronic fatigue.
This study is important because it challenges the clinical relevance of a serologic test once thought to be specific for symptomatic EBV infection in chronically fatigued patients. For ME/CFS patients and providers, it demonstrates that elevated EBV early antigen antibodies alone should not be used to confirm diagnosis or predict outcome, potentially preventing misdiagnosis or reliance on a non-informative test.
This study does not prove that EBV plays no role in ME/CFS pathophysiology or that EBV reactivation never occurs in patients with chronic fatigue. It only demonstrates that this particular antibody test is not clinically useful for diagnosis or prognosis—not that the underlying viral biology is irrelevant. The study also does not assess whether other EBV serologic markers or viral load measures might be more informative.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →